Support liposarcoma research with the Liddy Shriver Sarcoma Initiative!
The Liddy Shriver Sarcoma Initiative has funded $600,000 in liposarcoma research studies by respected investigators around the world. Recipients of the Initiative’s grants agree to publish both an experimental plan and a study report at SarcomaHelp.org. These reports allow people everywhere to learn from the research that we fund. We are proud of this level of transparency and accountability, and we believe that donors have a right to know how their money is used!
At the Initiative, we also believe that quality research should be funded wherever it is done, and we encourage collaborative efforts between departments, institutions and countries. We hope that the results of these research studies will be stepping stones to finding a cure for sarcoma.
DEDICATED TO MAKING THE MOST OF DONATIONS
The Liddy Shriver Sarcoma Initiative is a small, dedicated organization. We maintain an extremely low overhead of 2-3% per year. Thus, 97-98% of the funds we receive go directly to support sarcoma research.
Note: The Razoo service allows us to process credit card donations and fundraise more efficiently. Each donation comes to us after a 2.9% fee is taken for this service.
The mission of the Liddy Shriver Sarcoma Initiative is to improve the quality of life for people dealing with sarcoma. The Initiative increases public awareness of sarcoma, raises funds to award research grants, and provides support and timely information to sarcoma patients, their families, and medical professionals. These efforts are achieved through collaboration with numerous individuals and organizations that share a similar vision.
OUR TAX-EXEMPT STATUS
The Liddy Shriver Sarcoma Initiative is a Collective Giving Fund within FJC, a 501(c)(3) Not-for-Profit Public Charity and a Foundation of Philanthropic Funds. As such, all donations and gifts made to FJC that are designated for the Liddy Shriver Sarcoma Initiative are tax-deductible donations to the extent allowed by United States law.